Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:alsoKnownAs |
gptkb:TAK-003
|
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:Brazil
gptkb:European_Union gptkb:Indonesia |
| gptkbp:ATCCode |
J07BX06
|
| gptkbp:contains |
live attenuated dengue virus
|
| gptkbp:dosingSchedule |
two doses, three months apart
|
| https://www.w3.org/2000/01/rdf-schema#label |
Qdenga
|
| gptkbp:indication |
individuals aged 4 years and older
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
injection
|
| gptkbp:sideEffect |
fever
fatigue headache muscle pain injection site pain |
| gptkbp:targetsSerotypes |
gptkb:DENV-1
gptkb:DENV-2 gptkb:DENV-3 gptkb:DENV-4 |
| gptkbp:usedFor |
dengue fever
|
| gptkbp:website |
https://www.takeda.com/newsroom/newsreleases/2022/qdenga-eu-approval/
|
| gptkbp:bfsParent |
gptkb:Dengue_Fever
|
| gptkbp:bfsLayer |
5
|